Gilead Sciences, Inc.

Gilead Pharmasset LLC

Salesforce Com, Inc.

Conmed Corporation

Anchor Products Company

Other

James G Taylor

Jeromy J Cottell

John O Link

Elizabeth M Bacon

Zheng-Yu Yang

Sheila M Zipfel

Nathan E Wright

Darryl Kato

Hyung-Jung Pyun

Eda Y Canales

Chienhung Chou

Scott D Schroeder

Teresa Alejandra Trejo Martin

Evan S Krygowski

Gediminas J Brizgys

Randall W Vivian

Manoj C Desai

Michael L Mitchell

Thorsten A Kirschberg

Elbert Chin

William John Watkins

Chinh Viet Tran

Ashley Anne Katana

Scott E Lazerwith

Lianhong Xu

Winston C Tse

Stephen E Ammann

Adam James Schrier

Robert H Thrun

Randall Halcomb

Michael Sangi

Roland D Saito

Gary Bruce Phillips

Michael Graupe

Jay P Parrish

Jianyu Sun

Richard L Mackman

Choung U Kim

Aesop Cho

Musong Kim

Gayatri Balan

Kapil Kumar Karki

Dustin S Siegel

Qi Liu

Jeff A Zablocki

Craig David Weissman

Chandrasekar Venkataramani

Hongyan Guo

Hongtao Liu

Barton W Phillips

Tetsuya Kobayashi

Haolun Jin

Jiayao Li

Petr Jansa

Jennifer Anne Treiberg

Rick Andrew Lee

Jennifer R Zhang

Simon Zak Fell

Richard Y Huang

Michael O'Neil Hanrahan Clarke

Donovan Schneider

Paul A Roethle

Samuel E Metobo

James D Trenkle

Chao-I Hung

Marilyn Ndukwe

Neil H Squires

Kirk L Stevens

Ruben Martinez

Nathan D Shapiro

Chien-Hung Chou

Christopher T Clark

Rhiannon Thomas-Tran

Kevin Oliver

Zhenhong R Cai

Eric Gorman

Bill C Eidson

Philip Anthony Morganelli

Michael R Mish

Eli Levine

Xiaowu Chen

Mingzhe Ji

Joshua J Van Veldhuizen

Jonathan Bruce

Simon Toens

Jennifer Alissa Loyer-Drew

Ryan McFadden

Stephane Perreault

Bruce Ross

Kerim Babaoglu

Daniel H Byun

Jonathan Clive Tripp

Katie Ann Keaton

Steven S Bondy

Ana Zurisadai Gonzalez Buenrostro

David W Lin

Michael J Taylor

Xiaochun Han

Gregg M Schwarzwalder

Paul Hrvatin

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I): Wherein the variable substituents are described herein.

Tetracyclic compounds and methods for the treatment of Zika virus infection

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.

Pyrrolo[1,2-b]pyridazine derivatives

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Inhibitors of peptidylarginine deiminases

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

Provided is a tissue retrieval bag. The bag is defined by a region of the bag defining an opening; an exterior surface of the bag depending from the opening; and a channel formed into the exterior surface of the bag, wherein the channel provides access to the interior of the bag through the exterior surface. Also provided is a tissue retrieval defined by a region of the bag defining an opening; an exterior surface of the bag depending from the opening; and at least one porthole on the exterior of the bag, wherein at least one tube extends from the at least one porthole.

Tissue specimen retrieval bag, method for retrieving tissue

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Thiadiazole IRAK4 inhibitors

Provided herein are compounds of Formula (I):

Pentacyclic derivatives as Zika virus inhibitors

Growing community of inventors

Burlingame, CA, United States of America

James G Taylor